Synairgen plc (SYGGF)

Market Cap	110.27K
Revenue (ttm)	n/a
Net Income (ttm)	-8.53M
Shares Out	1.10B
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	3,524
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	1.45
RSI	32.83
Earnings Date	Dec 26, 2025

About Synairgen

Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein, which orchestrates the body's antiviral responses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 34
• Stock Exchange: OTCMKTS
• Ticker Symbol: SYGGF

Financial Performance

Financial numbers in GBP